Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

This study has been completed.
Sponsor:
Collaborators:
Korean Center for Disease Control and Prevention
International Tuberculosis Research Center
Novartis Institute for Tropical Medicine
Asian Medical Center
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )
ClinicalTrials.gov Identifier:
NCT00816426
First received: December 31, 2008
Last updated: August 27, 2014
Last verified: March 2014
  Purpose

This study, conducted jointly by researchers at the National Masan TB Hospital, Asan and Samsung Medical Centers in Seoul, Republic of Korea, and the Yonsei University and the NIH in the United States, will examine why some patients with tuberculosis (TB) develop disease that is harder to treat than most cases. TB is an infection of the lung that usually can be successfully treated with anti-TB drugs. However, some people get a more serious kind of disease (called multi-drug resistant TB or extensively drug-resistant TB) that is very difficult to treat and may not be cured by the regular medicines available. This study will try to find out if some of the common TB drugs are getting to the place where the TB bacteria are. It will also look at how current anti-TB drugs might be used more effectively and how better drugs might be developed.

People 20 years of age and older with hard-to-treat TB who have elected to undergo surgical removal of part of their lung at the National Masan Tuberculosis Hospital, Masan, the Asan Medical Center, and the Samsung Medical Center, may be eligible for this study.

Participants undergo the following procedures:

  • Medical history and physical examination, including sputum sample.
  • Blood tests at various times during the study.
  • Drug administration. Subjects are given one dose each of five common TB drugs rifampicin, isoniazid, pyrazinamide, kanamycin and moxifloxacin before they undergo surgery to remove part of their lung. After surgery, some of the lung tissue and fluid around the lungs that was removed during surgery will be examined to determine the regions where the TB bacteria live and analyze the lung tissue itself.
  • Dynamic MRI (magnetic resonance imaging) scan. This type of scan uses a magnetic field and radio waves to produce pictures of the lung. Subjects lie very still on a table inside the cylindrical scanner with their head on a soft cradle and their hands over their head. Several images are obtained for less than 5 minutes at a time.

Condition Intervention Phase
Tuberculosis
Drug: RIF
Drug: INH
Drug: PZA
Drug: KM
Drug: MXF
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Comparison between the relative permeability coefficients of RIF and KM in pathologically defined large caseous necrotic nodules.

Secondary Outcome Measures:
  • Comparison between the relative permeability coefficients of INH, PZA, and MXF in caseous necrotic nodules to that of RIF and KM; comparison between the relative permeability coefficients of RIF, KM, INH, and MXF.

Estimated Enrollment: 25
Study Start Date: December 2008
Study Completion Date: August 2014
Intervention Details:
    Drug: RIF
    N/A
    Drug: INH
    N/A
    Drug: PZA
    N/A
    Drug: KM
    N/A
    Drug: MXF
    N/A
Detailed Description:

It takes 6 to 24 months of intensive combination therapy to cure tuberculosis (TB) with antibiotics that have proven activity in vitro. In contrast, many pulmonary infectious diseases can be cured following single drug treatment with similar drugs for only one to a few weeks. We hypothesize that the unusual complexity of TB lesions and the degree of sequestration of TB bacilli within these lesions may limit access of the drugs to their site of action, leading to treatment failure, long treatment duration and the emergence of drug resistance. To test the hypothesis that drug maldistribution into lesions impacts on treatment duration and failure, we propose to examine the lesion-specific penetration properties of 5 standard anti-TB drugs in the lungs of subjects selected for lung surgery. The study is designed to understand what lesion types are the most difficult to penetrate. This aspect of TB drug pharmacokinetics has been largely neglected so far, probably owing to the lack of adequate technology and the limited availability of human TB lesion samples. Fifteen patients who elect lung resection surgery will be asked to participate in the study. Consented subjects will receive 4-5 first and second line anti-TB drugs concomitantly at 1 of 5 pre-determined times prior to surgery. At the time of resection, drug levels will be measured in plasma, in uninvolved lung tissue and in lesions using standard analytical methods as well as imaging Mass Spectrometry (MS) where drug concentration gradients can be visualized across tissue sections. The major aim of this study is to determine actual concentrations and permeability coefficients of the 5 study drugs in various lesion types contained within subjects surgically removed lung tissue. Data analysis will also provide the relative exposure of each drug in plasma versus lung tissue and lesion. If conclusive, the results may be taken into consideration when selecting drug doses and dosing regimens. Additionally, images generated by standard of care (SOC) High Resolution Computed Tomography (HRCT), and Dynamic MRI for each subject will provide information regarding lesion structure and anatomy, lesional blood flow and microvascular function. Lesion-specific correlations will be established between CT radiology and drug pharmacokinetic (PK) to identify which histopathologic lesion types may be particularly difficult to sterilize and to evaluate the potential impact of drug penetration on treatment outcome. The long term goal of this study is to identify the factors behind poor lesion penetration, so that new agents can be optimized with better penetration properties to target harder-to-sterilize lesion' types.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

    1. Males and females age 20 and above
    2. Selected for lung resection due to anti-tuberculous treatment failure, multidrug resistant disease, or other reason determined by the treating physician
    3. Radiographic evidence of tuberculous disease of the lung(s)
    4. If already on an aminoglycoside, ability and willingness to substitute this aminoglycoside with KM for the one study dose
    5. Willingness to receive MRI scan and marker and Gadolinium injection
    6. Willingness to have samples stored
    7. Ability and willingness to give written or oral informed consent

EXCLUSION CRITERIA:

  1. Subjects less than 20 years of age
  2. Women of childbearing potential who are pregnant, breast feeding, or unwilling to avoid pregnancy (i.e., the use of appropriate contraception including oral and subcutaneous implantable hormonal contraceptives, condoms, diaphragm, intrauterine device (IUD), or abstinence from sexual intercourse) [Note: Prospective female participants of childbearing potential must have negative pregnancy test (urine) within 48 hours prior to study entry.]
  3. Allergy or hypersensitivity to any of the 5 study drugs, any aminoglycoside, or rifamycin (those allergic to fluoroquinolones will not receive MXF).
  4. Those with severe gout
  5. Severe claustrophobia or Gadolinium hypersensitivity (tbc)
  6. Renal, hepatic, auditory and/or vestibular impairment.

    1. Serum creatinine greater than 2.0 mg/dL (renal)
    2. Aspartate aminotransferase (AST or SGOT) greater than 100 IU/L (LFTs)
    3. Alanine aminotransferase (ALT or SGPT) greater than 100 IU/L (LFTs)
    4. Total bilirubin greater than 2.0 mg/dL (LFTs)
  7. The use of any of Rifampicin (RIF), Rifapentine or Rifabutin within 30 days prior to the study
  8. HIV infection, determined by a positive HIV test performed with the past 6 months
  9. The use of any of the following drugs within 30 days prior to study:

    1. Systemic cancer chemotherapy
    2. Systemic corticosteroids (oral or IV only) with the following

      exceptions (i.e.the following are NOT exclusion criteria): intranasal, topical, and inhaled corticosteroids, a short course (10 days or less) of corticosteroids for a non-chronic condition completed at least 2 weeks prior to enrollment in this study

    3. Systemic IND agents other than Linezolid
    4. Antiretroviral medications
    5. Growth factors
  10. The need for ongoing therapy with warfarin, phenytoin, lithium cholestrymine, levodopa, cimetidine, disulfiram, ergot derivatives, fosphenytoin, carbamazepine, cyclosporine, tacrolimus, sirolimus, amiodarone or Phenobarbital (If a potential subject is on one of these medications but it is being stopped per standard of care, to be eligible for the study the drug must be stopped at least one day prior to receiving study drug. A longer washout period is not necessary.) The only exception to this is amiodarone; because of amiodarone s long half-life and potential for QT prolongation, it should be stopped at least 60 days prior to receiving study drugs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00816426

Locations
United States, New Jersey
Rutgers University, New Jersey Medical School
Newark, New Jersey, United States
Korea, Republic of
Pusan National Unversity Hospital (PNUH)
Busan, Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Korean Center for Disease Control and Prevention
International Tuberculosis Research Center
Novartis Institute for Tropical Medicine
Asian Medical Center
Investigators
Principal Investigator: Clifton E Barry, Ph.D. National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

Publications:
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )
ClinicalTrials.gov Identifier: NCT00816426     History of Changes
Other Study ID Numbers: 999909061, 09-I-N061
Study First Received: December 31, 2008
Last Updated: August 27, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Tuberculosis
Lesions
Pharmacokinetics
Maldistribution
Histopathology

Additional relevant MeSH terms:
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on October 21, 2014